IDIOPATHIC PULMONARY FIBROSIS

This study looks at the long-term safety of an inhaled medication called treprostinil for people with fibrotic lung diseases like idiopathic pulmonary fibrosis. About 1,850 adults who completed a prior related study will take the drug and be monitored for side effects. The goal i…

This study is developing a new way to treat pulmonary fibrosis, a condition where the lungs become scarred and stiff. The approach uses tiny particles called liposomes, coated with hyaluronic acid, to deliver drugs directly to the cells that cause scarring. The research is being …

This trial tests an investigational drug called CAL101 in 150 adults with idiopathic pulmonary fibrosis, a disease that scars the lungs and makes breathing harder. Participants receive monthly IV infusions of CAL101 or a placebo for 6 months. The goal is to see if CAL101 can prev…

This study tests an experimental tablet called HEC585 in 270 adults with idiopathic pulmonary fibrosis (IPF), a disease that scars the lungs and makes breathing harder. Participants receive either HEC585, a placebo (dummy pill), or an active comparator (Pirfenidone) to see if HEC…

This study tests a drug called axatilimab in 145 people with idiopathic pulmonary fibrosis (IPF), a disease that scars the lungs and makes breathing hard. The goal is to see if the drug can slow down the decline in lung function over 26 weeks compared to a placebo. Participants w…

This study tests an experimental drug called BMS-986278 in 1255 adults with idiopathic pulmonary fibrosis (IPF), a disease that causes progressive lung scarring. The goal is to see if the drug can slow the decline in lung function and is safe to take. Participants will receive ei…

This phase 2 trial tests an experimental drug called ENV-101 (taladegib) in 213 adults with idiopathic pulmonary fibrosis, a disease that causes lung scarring and makes breathing harder. Participants take either the drug or a placebo daily for several months. The main goal is to …

This early-stage study tests whether atezolizumab, a drug used for cancer, is safe for people with idiopathic pulmonary fibrosis (IPF), a disease that causes lung scarring and breathing problems. About 24 adults aged 50 and older with confirmed IPF will receive the drug. Research…

This phase 2 trial tests a new drug called LYT-100 (deupirfenidone) in 240 adults with idiopathic pulmonary fibrosis (IPF), a lung disease that causes scarring and breathing difficulty. Participants receive either LYT-100, the existing drug pirfenidone, or a placebo. The main goa…

This study looks at whether training one leg at a time on a bike can help people with idiopathic pulmonary fibrosis (IPF) exercise longer. IPF makes it hard to breathe, so using fewer muscles may allow a better workout. The trial will compare one-legged cycling to the usual two-l…

This study looks for biological markers in blood and lung samples from people with idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases. The goal is to find markers that can predict how the disease will progress and to group patients into subtypes. Researchers…

This study collects and analyzes blood, DNA, and tissue samples from 315 adults with pulmonary fibrosis, their relatives, and healthy volunteers. The goal is to learn more about the disease's causes, not to test a new treatment. Researchers hope the findings will guide future the…

This study at Duke University tests whether a special MRI scan using inhaled xenon gas can detect changes in lung function over time in people with progressive pulmonary fibrosis. Sixty adults with various types of lung scarring will have MRI scans before starting anti-fibrotic m…

This registry is following 867 people with idiopathic interstitial pneumonias (IIPs), a group of rare lung diseases. The goal is to learn how these diseases behave over time, how they are diagnosed, and what treatments doctors currently use. No new drugs or procedures are being t…

This study tests whether a special MRI using inhaled xenon gas can show changes in lung function over time in people with idiopathic pulmonary fibrosis (IPF) who are starting approved treatments. About 34 participants will have an MRI before starting therapy and again at 3, 6, an…

This study looks at whether a molecule called miR200 in the blood can help detect idiopathic pulmonary fibrosis (IPF), a lung-scarring disease, at an early stage. Researchers will compare miR200 levels in 450 people: those with IPF, those with other lung diseases, and healthy vol…

This study looks at lung tissue from 80 people with pulmonary fibrosis to find unique genetic markers linked to scarring. By analyzing gene activity, researchers hope to better understand the disease and pave the way for new diagnostic tools and treatments. Participants must be 1…